Alcon Inc Stock Price, News & Analysis

Alcon (NYSE:ALC), the global leader in eye care, announced that CEO David Endicott will present at the 2025 Baird Global Healthcare Conference on September 9, 2025, at 9:05 a.m. ET. The presentation will be accessible via live webcast on the company's investor relations website.

Alcon serves over 260 million people in more than 140 countries annually through its Surgical and Vision Care products, focusing on conditions like cataracts, glaucoma, retinal diseases, and refractive errors. The company employs over 25,000 associates and maintains a 75-year heritage in eye care innovation.

Alcon (NYSE:ALC) reported Q2 2025 results with sales of $2.6 billion, up 4% on a reported basis and 3% in constant currency. The company posted diluted EPS of $0.35 and core diluted EPS of $0.76.

Key highlights include the successful US launch of Tryptyr, a first-in-class dry eye treatment, and the announced acquisition of STAAR Surgical to expand Alcon's myopia correction portfolio. The company generated $889 million in operating cash flow and returned $287 million to shareholders.

For 2025, Alcon updated its outlook, reducing net sales guidance to $10.3-10.4 billion (4-5% growth) and core operating margin to 19.5-20.5%, while maintaining core diluted EPS guidance of $3.05-3.15.

Alcon (NYSE:ALC), the global eye care leader, announced its participation in the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, present 10 medical affairs scientific exchange presentations, and feature a hands-on experience zone.

Key highlights include new data on Vivity®, an Extended Depth of Focus (EDOF) intraocular lens, supported by over 10 clinical studies involving more than 700 patients. The company will also present research on cataract surgery performed at physiologic IOP in patients with diabetic retinopathy. Additionally, Alcon will officially introduce UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), their next-generation Phaco/Vit platform, to the Indian market.

Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $28 per share in cash, representing a total equity value of approximately $1.5 billion. The deal offers a 59% premium to STAAR's 90-day VWAP.

The acquisition includes STAAR's EVO family of Implantable Collamer® Lenses (ICL), which provides vision correction for moderate to high myopia patients. This strategic move enhances Alcon's surgical vision correction portfolio, particularly targeting the growing myopia market, expected to affect 50% of the world's population by 2050.

The transaction is expected to close within 6-12 months, subject to regulatory and STAAR shareholder approval, and become earnings accretive in year two. Alcon plans to finance the acquisition through short- and long-term credit facilities.

Alcon (NYSE:ALC) has received Health Canada approval for its UNITY® Vitreoretinal Cataract System (VCS), marking the first innovation from its Unity portfolio. The breakthrough surgical technology combines vitreoretinal and cataract surgical capabilities in one integrated platform.

The system delivers significant improvements over Alcon's current CONSTELLATION® and CENTURION® systems, featuring up to 2x faster nucleus removal with 40% less energy, and the world's fastest vitrectomy probe at 30,000 cuts per minute. The platform includes a novel phacoemulsification modality and a first-of-its-kind phaco handpiece that estimates incision site temperature.

Following successful testing with over 200 surgeons from 30+ countries, Unity VCS is scheduled for commercial launch in early 2026.

Alcon (SIX/NYSE: ALC) announced its intention to acquire LumiThera, Inc. and its photobiomodulation (PBM) device for treating early and intermediate dry Age-Related Macular Degeneration (AMD). The PBM device, which received FDA authorization in November 2024 and CE Mark in November 2018, is the first technology demonstrating meaningful visual improvement in dry AMD patients over two years of treatment.

The pivotal LIGHTSITE III study showed significant results: 88% of patients maintained or gained vision, and 64% gained at least one line of visual acuity. The device is currently available in Europe, Latin America, Singapore, the UK, and the US. The acquisition, excluding LumiThera's diagnostic devices, is expected to close in Q3 2025, subject to customary conditions and shareholder approval.

Alcon (NYSE:ALC), the global eye care leader, has achieved certification as a Top Employer in Canada for 2025 by the Top Employers Institute. The recognition highlights Alcon Canada's excellence in key areas including People Strategy, Career Development, Rewards and Recognition, Purpose and Values, and Diversity & Inclusion.

The company's strengths include its comprehensive learning programs, leadership development initiatives, and commitment to sustainability, aiming for carbon neutrality by 2030. Alcon Canada's Head Office maintains ISO 14001:2015 Environmental Management System certification and demonstrates strong ethical business practices, including compliance with the Accessibility for Ontarians with Disabilities Act.

Alcon (NYSE: ALC) has announced the approval of Clareon PanOptix Pro intraocular lens (IOL) in Canada for cataract patients. The new IOL features ENLIGHTEN NXT Optical technology, delivering industry-leading performance with 94% light utilization (compared to theoretical maximum of 96%) and half the light scatter of its predecessor. Key improvements include enhanced light distribution and a 16% increase in optical image contrast between distance and intermediate vision. The device builds upon PanOptix's established success as the world's most implanted trifocal IOL, maintaining its low visual disturbance profile and high patient satisfaction. PanOptix Pro will be available in Canada in early 2026 through the Clareon AutonoMe preloaded delivery system and Clareon Monarch IV delivery system, offering +2.17 diopter intermediate and +3.25 diopter near add power.

Alcon (NYSE: ALC) has received FDA approval for TRYPTYR (acoltremon ophthalmic solution) 0.003%, a first-in-class treatment for Dry Eye Disease (DED). The drug, which works as a TRPM8 receptor agonist, demonstrated significant efficacy in Phase 3 trials involving over 930 patients. Up to four times more TRYPTYR patients experienced increased natural tear production compared to the control group, with results visible as early as Day 1.

The treatment, administered as one drop per eye twice daily, addresses a significant market need, as approximately 38 million Americans suffer from DED, with less than 10% receiving prescription treatment. Alcon plans to launch TRYPTYR in the U.S. during Q3 2025.

[ "First-in-class TRPM8 receptor agonist showing rapid efficacy as early as Day 1", "Strong Phase 3 trial results with up to 4x more patients showing improved tear production vs. placebo", "Addresses large untapped market of 38 million U.S. patients with DED", "First prescription pharmaceutical treatment approval since Alcon became independent" ]